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Cinacalcet HCl attenuates parathyroid hyperplasia in a rat
model of secondary hyperparathyroidism.
Background. Secondary hyperparathyroidism (HPT) in
chronic kidney disease (CKD) is a physiologic response to
kidney failure characterized by elevated serum parathyroid
hormone (PTH) levels and parathyroid gland enlargement.
Calcimimetic agents acting through allosteric modification of
the calcium-sensing receptor (CaR) can attenuate parathyroid
hyperplasia in rats with secondary HPT. The present study ex-
plores the effects of the calcimimetic cinacalcet HCl on parathy-
roid hyperplasia, apoptosis, and PTH secretion in a rat model
of secondary HPT.
Methods. Cinacalcet HCl was gavaged daily (1, 5, or 10 mg/kg)
for 4 weeks starting 6 weeks post-5/6 nephrectomy. After dos-
ing, hyperplasia was determined using parathyroid weight and
proliferating cell nuclear antigen (PCNA) immunochemistry.
Apoptosis was determined using in situ techniques. Serum
PTH(1–34) and blood chemistries were determined throughout
the course of the study.
Results. Administration of cinacalcet HCl (5 or 10 mg/kg)
significantly reduced the number of PCNA-positive cells and
decreased parathyroid weight compared with vehicle-treated
5/6 nephrectomized rats. There was no difference in apoptosis
from cinacalcet HCl–treated or vehicle-treated animals. Serum
PTH and blood ionized calcium levels decreased in cinacalcet
HCl–treated animals compared with vehicle-treated controls.
Conclusion. The results confirm previous work demon-
strating that calcimimetic agents attenuate the progression of
parathyroid hyperplasia in subtotally nephrectomized rats, ex-
tending earlier observations to now include cinacalcet HCl.
These results support a role for the CaR in regulating parathy-
roid cell proliferation. Therefore, cinacalcet HCl may represent
a novel therapy for improving the management of secondary
HPT.
Parathyroid cells secrete parathyroid hormone (PTH)
and play a central role in maintaining circulating lev-
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els of ionized calcium. In contrast to normal adults,
where proliferation and growth of the parathyroid
glands is maintained at a low level, abnormally in-
creased parathyroid cell proliferation (hyperplasia) is
characteristic of hyperparathyroidism (HPT) secondary
to chronic kidney disease (CKD) [1]. Although the
mechanisms are not precisely defined, the onset of
parathyroid hyperplasia due to CKD involves sev-
eral factors, such as 1,25-dihydroxyvitamin D3 [vita-
min D3 (calcitriol)] deficiency, phosphorus retention,
and hypocalcemia [2–4]. In addition, down-regulation
of vitamin D receptor (VDR) and calcium-sensing re-
ceptor (CaR) expression may contribute to the over-
all pathogenesis of parathyroid hyperplasia [3, 4]. Since
CKD results in impaired renal production of cal-
citriol, current therapies use exogenously administered
calcitriol or other vitamin D sterols to repress
both parathyroid cell proliferation and PTH synthesis
[4, 5].
In CKD, phosphorus retention by the kidney results in
high levels of serum phosphorus that worsen secondary
HPT by enhancing parathyroid cell proliferation and
PTH synthesis and secretion. Indirectly, high phosphate
levels also mediate a reduction in serum calcitriol and
blood ionized calcium levels [3, 4]. Although phospho-
rus restriction and/or the use of phosphate binders can
ameliorate parathyroid hyperplasia [6, 7], potentially se-
rious adverse clinical consequences have been associated
with these types of therapeutic approaches to manage-
ment of secondary HPT. Theses results have prompted
investigators to search for alternative therapeutic targets
mediating parathyroid hyperplasia and/or the control of
PTH secretion/production. The main regulator of PTH
secretion is serum calcium. Accordingly, one target is the
CaR, a G protein–coupled receptor in the membrane
of the parathyroid cells that modulates the minute-to-
minute release of PTH into the circulation. Activation
of the parathyroid cell receptor by calcium increases in-
tracellular calcium concentration and results in abrupt
decreases in PTH secretion [8, 9].
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Calcimimetic compounds are low-molecular-weight
phenylalkylamine derivatives that act as allosteric mod-
ulators of the CaR. These compounds enhance the sen-
sitivity of the CaR to extracellular calcium, thus exerting
a suppressive effect on PTH secretion [10]. In addition,
calcimimetic agents can impede parathyroid gland hyper-
plasia in subtotally nephrectomized rats [11]. Cinacalcet
HCl, an allosteric modulator of the CaR, has recently
been approved for the treatment of secondary HPT in
patients with CKD on dialysis, and has been shown to re-
duce PTH secretion both in vitro (bovine parathyroid cell
assay) and in vivo (normal rats) [12]. Furthermore, in clin-
ical studies, cinacalcet HCl has shown promise as a novel
therapeutic for the treatment of secondary HPT [13–15].
The present report describes the effects of cinacalcet HCl
on parathyroid gland hyperplasia, PTH secretion, and
parathyroid apoptosis in an in vivo model of chronic re-
nal insufficiency, 5/6 nephrectomized rats with secondary
HPT.
METHODS
Male Sprague-Dawley rats (Charles River Laborato-
ries, Wilmington, MA, USA) weighing 300 to 350 g were
used in these studies. One week after arrival, animals
were rendered uremic using a two-step partial ligation
procedure or were sham-operated. All animals received
standard lab chow (Harlan Teklad, Madison, WI, USA)
containing 1.17% calcium and 1.00% phosphorus and wa-
ter ad libitum. The animal protocol was approved by the
Institutional Animal Care and Use Committee of Am-
gen, Inc. (Thousand Oaks, CA, USA).
5/6 nephrectomy model of renal insufficiency
CKD accompanied by secondary HPT was induced in
male Sprague-Dawley rats by 5/6 nephrectomy, a pro-
cedure that reduces the original functional renal mass
by five sixths. In the first surgery, animals were anes-
thetized by an intramuscular injection (0.1 mL) of a
combination of two parts ketamine (100 mg/mL), one
part xylazine (100 mg/mL), and 0.3 parts acepromazine
(10 mg/mL). The left kidney was exposed, after which the
renal artery was located and the uppermost bifurcation
(two branches) sutured. Following a 1-week recovery pe-
riod, animals were again anesthetized and the right kid-
ney was removed. Control animals (shams) were similarly
anesthetized and subjected to surgical procedures with-
out suturing the renal artery branches or removing the
kidney. Following the surgical procedures, animals were
returned to their home cages. Animals were weighed
throughout the course of treatment to assess whether
drug treatment caused any weight loss.
Cinacalcet HCl dosing for 4 weeks
Starting 6 weeks postsurgery, 5/6 nephrectomized (N =
35) and sham (N = 18) animals received orally either ve-
hicle (20% captisol in water) (mL/kg) or cinacalcet HCl
(1, 5, or 10 mg/kg) for 4 weeks. Sampling for the deter-
mination of serum PTH and serum chemistries after the
initiation of cinacalcet HCl treatment began at the 8-week
time point (see Figs. 4 and 5).
Blood collection for PTH and serum chemistry profile
Blood for the determination of serum PTH, phospho-
rus, and blood ionized calcium levels was collected at 0
(1 week postsurgery), 2, 4, and 6 weeks. At week 6, ve-
hicle or drug treatment was initiated; therefore, the first
posttreatment blood sample to be collected was at week
8. At weeks 8 and 10, blood was collected 2 hours after
drug/vehicle treatment. For measurement of blood ion-
ized calcium levels, blood was collected from the orbital
sinus of anesthetized rats (2% isofluorane in O2) with
heparinized capillary tubes and analyzed using a Ciba-
Corning 634 ISE Ca++/pH Analyzer (Ciba-Corning Di-
agnostics Corp., Medfield, MA, USA). Separately, blood
was collected for PTH, blood urea nitrogen (BUN), cre-
atinine, and serum phosphorus levels into SST (clot acti-
vator) brand blood tubes (BD, Franklin Lakes, NJ, USA)
and allowed to clot. Serum was removed and stored at
−70◦C until assayed. PTH levels were quantified accord-
ing to the vendor’s instructions using a rat PTH[1–34] im-
munoradiometric assay kit (Immutopics, San Clemente,
CA, USA). BUN, creatinine, and phosphorus levels were
determined using a blood chemistry analyzer (Olympus
AU 400) (Melville, NY, USA).
Proliferating cell nuclear antigen (PCNA)
immunohistochemistry
The laryngo-tracheal complex was removed at sacri-
fice and stored 2 to 3 days in zinc-buffered formalin,
then transferred to 70% alcohol and trimmed. At trim-
ming, the parathyroids were dissected away from the thy-
roid and blotted dry on a lint-free Kim wipe (Kimberly
Clark Corp., Roswell, GA, USA) prior to being individu-
ally weighed on a Sartorius BP211D balance (Go¨ttingen,
Germany). Parathyroids were then processed for paraf-
fin embedment. After embedding, 5 lm sections were cut
and placed onto charged slides (VWR Scientific, West
Chester, PA, USA). Immunostaining was performed on
the sections according to the vendor’s instructions using a
PCNA staining kit (Zymed Laboratories, Inc., South San
Francisco, CA, USA). Ileum tissue from the 5/6 nephrec-
tomized animals were also processed for PCNA im-
munostaining and used as a measure of general toxemia.
Parathyroid area was determined through the use
of an area-measurement graticle containing a series
of 0.01 mm2 grids (area initially determined using a
calibrated graticle) overlaying the central region of a
parathyroid section. Sections were taken from approx-
imately the same level of individual parathyroids. Tissue
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samples were visualized at 100× on a Leitz Laborlux mi-
croscope (Wetzlar, Germany), and the number of grids
overlaying the parathyroid tissue was counted. The to-
tal area of the parathyroid was thus determined by mul-
tiplying the number of grids by 0.01 mm2, after which
the number of PCNA-positive cells in the gridded sec-
tional area were counted and expressed as the number of
PCNA-positive cells/mm2. Slides were coded and an ob-
server who was unaware of treatment group assignment
performed quantification of parathyroid proliferation.
Apoptosis
To identify apoptosis in parathyroid glands from
5/6 nephrectomized or sham rats treated with vehicle
[phosphate-buffered saline (PBS)] or cinacalcet HCl
(10 mg/kg), nuclear DNA fragmentation was measured in
situ using the Apoptag System (Serologicals Corporation,
Atlanta, GA, USA). Briefly, parathyroid gland sections
from animals treated with vehicle or cinacalcet HCl were
digested with 20 lg/mL proteinase K (Sigma Chemical
Company, St Louis, MO, USA) in 0.1 mol/L PBS at room
temperature for 15 minutes and incubated with 3% hy-
drogen peroxide/methanol for 5 minutes to block endoge-
nous peroxidase. Sections were incubated for 1 hour at
37◦C with terminal deoxynucleotidyl transferase (TdT)
to label exposed 3′-OH DNA ends with digoxigenin-
tagged nucleotides. Digoxigenin-labeled DNA was de-
tected by the immunoperoxidase method. Sections were
developed with 3,3′-diaminobenzidine (DAB), and the
nuclei of apoptotic cells were stained brown. The speci-
ficity for apoptosis was verified by negative staining when
distilled water was substituted for TdT. Positive control
samples were provided by Serologicals Corporation.
Statistical analysis
Results were expressed as the mean ± standard error.
All data were initially subjected to a two-way analysis
of variance (ANOVA), followed by post hoc analysis us-
ing Fisher protected least square difference (PLSD) test.
The Mann-Whitney test or unpaired Student t test was
utilized for two-group comparisons. Significance was set
a priori at a <0.05 for all comparisons. Grubb’s outlier
test was also used (GraphPad Software Inc., San Diego,
CA, USA). The correlations between serum parameters
(PTH, ionized calcium, and phosphorus) vs. parathyroid
weight or PCNA-positive cell count were analyzed using
Pearson’s correlation test.
RESULTS
Confirmation of secondary HPT induction
Six weeks after surgery, statistically significant in-
creases in serum BUN (P < 0.001) and creatinine (P <
0.001) were observed, indicating CKD was successfully
induced (Table 1). Serum PTH (P < 0.001) and phos-
Table 1. Serum biochemical indices from sham and 5/6
nephrectomized animals 6 weeks postsurgery
Sham 5/6 nephrectomy
(N = 18) (N = 35)
Blood urea nitrogen mg/dL 16.0 ± 0.4 32.3 ± 1.4a
Creatinine mg/dL 0.32 ± 0.013 0.78 ± 0.031a
Phosphorus mg/dL 5.07 ± 0.13 6.54 ± 0.34b
Ionized calcium mmol/L 1.485 ± 0.010 1.452 ± 0.009c
Parathyroid hormone pg/mL 187 ± 20 959 ± 77a
Significant differences in serum blood urea nitrogen, creatinine, blood ionized
calcium, phosphorus, and parathyroid hormone levels were observed between
sham versus 5/6 nephrectomy animals. Values represent mean ± SEM.
aP < 0.0001; bP < 0.001; cP < 0.01.
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Fig. 1. Administration of cinacalcet HCl reduces parathyroid hyper-
plasia in 5/6 nephrectomy (Nx) rats. Male Sprague-Dawley rats were
treated orally with cinacalcet HCl or vehicle daily for 4 weeks beginning
6 weeks post-5/6 nephrectomy. The values for proliferating cell nuclear
antigen (PCNA)-positive cells are mean ± SEM of 9 to 17 sections.
One section per parathyroid was taken for PCNA-positive cell analysis.
∗∗∗P < 0.001 cinacalcet HCl–treated animals vs. vehicle-treated animals.
phorus (P < 0.01) levels were significantly higher in 5/6
nephrectomized animals (N = 35) when compared to
sham controls (N = 18), and Ca2+ levels were signifi-
cantly lower (P < 0.05) (Table 1). These alterations are
consistent with the pathophysiology of secondary HPT
in rodents that has been previously described in detail
[2, 11]. There were no significant differences in body
weights among the treatment groups [e.g., at 10 weeks
postnephrectomy body weights (mean ± SEM) were 5/6
nephrectomy 10 mg/kg = 495 ± 8 g; 5/6 nephrectomy ve-
hicle = 466 ± 17 g; sham 10 mg/kg = 476 ± 12 g; sham
vehicle = 491 ± 17 g].
Effect of cinacalcet HCl on parathyroid gland weight,
area, and hyperplasia
Administration of cinacalcet HCl at 5 and 10 mg/kg
doses for 4 weeks starting 6 weeks post-5/6 nephrec-
tomy resulted in a significant (P < 0.001) reduction in the
number of PCNA-positive cells compared with vehicle-
treated 5/6 nephrectomy animals (Figs. 1 and 2) (Table 2).
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Table 2. Effect of cinacalcet HCl or vehicle treatments on parathyroid weight and parathyroid proliferation in 5/6 nephrectomy and sham rats
5/6 nephrectomy Parathyroid No. of PCNA-positive No. of parathyroid
or sham Treatment weight mg parathyroids cells/mm2 sections
5/6 nephrectomy Vehicle 1.95 ± 0.18a 17 58.1 ± 8.9 17
5/6 nephrectomy Cinacalcet HCl (1 mg/kg) 2.17 ± 0.38 8 57.5 ± 10.1 8
5/6 nephrectomy Cinacalcet HCl (5 mg/kg) 1.53 ± 0.22 15 18.3 ± 3.4b 15
5/6 nephrectomy Cinacalcet HCl (10 mg/kg) 1.05 ± 0.13c 20 19.0 ± 6.4b 15
Sham Vehicle 0.46 ± 0.03 6 17.9 ± 2.7 6
Sham Cinacalcet HCl (1 mg/kg) 0.37 ± 0.04 6 17.7 ± 2.7 5
Sham Cinacalcet HCl (5 mg/kg) 0.49 ± 0.04 8 18.0 ± 3.9 8
Sham Cinacalcet HCl (10 mg/kg) 0.52 ± 0.07 8 16.3 ± 5.2 8
— Normal (control) rats 0.39 ± 0.06 9 18.7 ± 3.7 9
5/6 nephrectomy and sham rats were treated with oral administration of cinacalcet HCl or vehicle daily for 4 weeks beginning 6 weeks postsurgery. At 10 weeks
postsurgery, animals were sacrificed, parathyroid glands removed for determination of parathyroid weight and parathyroid hyperplasia by proliferating cell nuclear
antigen (PCNA). Data shown as mean ± SEM.
aP < 0.01, 5/6 nephrectomy vehicle vs. sham vehicle; bP < 0.001; cP < 0.05, 5/6 nephrectomy cinacalcet HCl vs. 5/6 nephrectomy vehicle. Normal (control) rats were
aged-matched and received no treatment or surgical manipulations.
Similarly, cinacalcet HCl resulted in a significant re-
duction in parathyroid gland weight (P = 0.022) in 5/6
nephrectomy animals, as determined by ANOVA. Addi-
tional post hoc analysis revealed a significant (P < 0.05)
reduction in parathyroid weight in the cinacalcet HCl
(10 mg/kg)-treated 5/6 nephrectomy animals compared
with vehicle-treated 5/6 nephrectomy animals (Table 2).
A 25% reduction in parathyroid weight was also observed
for those animals treated with 5 mg/kg cinacalcet HCl,
compared with vehicle treated 5/6 nephrectomy animals.
Mean parathyroid gland area was significantly greater
(P < 0.01) in 5/6 nephrectomized rats (1.14 ± 0.12 mm2)
when compared to rats that underwent the sham proce-
dure (0.47 ± 0.05 mm2). 5/6 nephrectomized rats treated
with cinacalcet HCl at 10 mg/kg showed a 25% reduction
in parathyroid gland area (0.87 ± 0.09 mm2) compared
to 5/6 nephrectomized rats treated with vehicle.
In sham animals, cinacalcet HCl had no effect on
parathyroid gland cell proliferation or parathyroid weight
compared with vehicle treatment (Table 2). Furthermore,
cinacalcet HCl had no effect on cell proliferation from
ileum tissue (Fig. 3), which was used as a measure of gen-
eral toxemia.
Effect of cinacalcet HCl on serum PTH, phosphorus, and
blood ionized calcium levels
Administration of cinacalcet HCl to 5/6 nephrec-
tomized animals for 4 weeks starting 6 weeks after surgery
resulted in a significant reduction in (P = 0.0001) on
serum PTH (Fig. 4A). The 8-week time point represented
the first blood collection for PTH determinations after
cinacalcet HCl administration had begun. Significant de-
creases in serum PTH levels were observed in both the 5
and 10 mg/kg dose groups at the 8-week and 10-week time
points (P < 0.05 for each). The 1 mg/kg dose of cinacal-
cet HCl caused no significant alterations in serum PTH
levels at the times studied.
In addition, cinacalcet HCl treatment had a significant
effect (P = 0.0001) on blood ionized calcium compared
with vehicle treatment (Fig. 4B). Decreases in blood
ionized calcium were significant in the 5 and 10 mg/kg
dose groups at all time points. Although the 1 mg/kg
cinacalcet HCl dose reduced blood ionized calcium, the
reductions were not significantly different from vehicle
controls.
No differences in serum phosphorus levels were ob-
served in cinacalcet HCl (10, 5, or 1 mg/kg) treated 5/6
nephrectomized animals (6.6 ± 0.4, 7.8 ± 1.0, and 9.4 ±
2.7 mg/dL, respectively) compared with vehicle-treated
5/6 nephrectomized animals (7.8 ± 0.8 mg/dL).
In sham animals, cinacalcet HCl treatment resulted
in a significant reduction in serum PTH levels (P <
0.001) (Fig. 5A). Additional analysis revealed significant
(P < 0.05) decreases in serum PTH levels occurred after
cinacalcet HCl treatment in sham animals in the 10 mg/
kg-dose group following 2 and 4 weeks of dosing (8 and
10 weeks) and were observed in the 5 mg/kg dose group
after 4 weeks of dosing (10 weeks).
Cinacalcet HCl treatment significantly reduced blood
ionized calcium levels (P < 0.0001) (Fig. 5B) in sham
animals. All doses of cinacalcet HCl resulted in significant
(P < 0.05) decreases in blood ionized calcium at the 8-
and 10-week time points, corresponding to 2 and 4 weeks
of drug administration, respectively.
No significant differences in mean serum phosphorus
levels were observed in the cinacalcet HCl (10 mg/kg)-
treated sham animals (5.8 ± 0.3 mg/dL) compared to
vehicle-treated sham animals (5.4 ± 0.2 mg/dL).
Correlation analysis
An analysis was performed to determine correlations
between parathyroid gland weight and PCNA-positive
cells with PTH, blood ionized calcium, and phosphorus
levels. Serum PTH, blood ionized calcium, and phospho-
rus levels were highly correlated with parathyroid weight
Colloton et al: Cinacalcet HCl attenuates parathyroid hyperlasia 471
Fig. 2. Sections from rat parathyroid glands (400×) (A) 5/6 nephrectomy vehicle, (B) 5/6 nephrectomy cinacalcet HCl 10 mg/kg, (C) sham vehicle,
and (D) sham cinacalcet HCl 10 mg/kg. Proliferating cell nuclear antigen (PCNA)-positive cells are shown as brown staining. Arrows indicate positive
cells (400×) (A to D). Cinacalcet HCl (B) treatment for 4 weeks in 5/6 nephrectomized animals decreases parathyroid gland proliferation when
compared to vehicle-treated 5/6 nephrectomized animals (A). Cinacalcet HCl has no effect on parathyroid gland proliferation in sham-operated
animals (C and D).
(Fig. 6). Similarly, serum PTH (r = 0.61, P = 0.01) and
blood ionized calcium (r = 0.47, P = 0.036) correlated
with number of PCNA-positive cells. No correlation ex-
isted between phosphorus (r = 0.069, P = 0.7) levels and
number of PCNA-positive cells.
Apoptosis
Very few or no apoptotic cells were found in parathy-
roid glands from either treatment group (data not
shown). The positive controls for each run, regressing rat
mammary gland, showed positive staining for apoptotic
cells.
DISCUSSION
The results of this study clearly demonstrate that
cinacalcet HCl, an allosteric modulator of the CaR [12],
reduces parathyroid cell proliferation in rats with sec-
ondary HPT, a conclusion consistent with that of Wada
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
Fig. 3. Ileum taken from a rat receiving either 5/6 nephrectomy treated
with vehicle (A) or cinacalcet HCl 10 mg/kg (B). Proliferating cell nu-
clear antigen (PCNA)-positive cells are shown as brown staining. Ar-
rows indicate positive cells (400×). There is no apparent difference in
cell proliferation in drug versus vehicle-treated animals.
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Fig. 4. Serum parathyroid hormone (PTH)
(A) and blood ionized calcium (B) levels in
5/6 nephrectomized rats treated daily with
oral cinacalcet HCl (•) 10 mg/kg (N = 10);
() 5 mg/kg (N = 10); () 1 mg/kg (N = 5);
or (◦) vehicle mL/kg (N = 10) for 4 weeks
starting 6 weeks post-5/6 nephrectomy. Serum
samples were taken 2 hours after dosing. 5/6
nephrectomy animals treated with cinacalcet
HCl had overall significant (P < 0.0001) lower
serum PTH and blood ionized calcium lev-
els. Post hoc analysis showed significant differ-
ences (∗P < 0.05) between treated vs. controls
at 8 and 10 weeks. Control normal animals
received no treatments (). Values represent
mean ± SEM (N = 5 to 10 animals per dose
group).
et al [11] linking the CaR and the development of parathy-
roid hyperplasia. This is the first study, however, that has
demonstrated reduced parathyroid cell proliferation with
cinacalcet HCl in a rodent model of secondary HPT. Al-
though the data generated do not allow us to explicitly
state that delayed cinacalcet HCl treatment can mediate
regression of parathyroid hyperplasia, recent preliminary
data suggest that this is possible [16]. The present data,
coupled with previous findings with NPS R-568 [11, 17,
18], offer encouraging support for efficient targeting of
the CaR with cinacalcet HCl in secondary HPT.
Based on pharmacokinetic exposure data in rats for
a 10 mg/kg dose, the area under the curve (AUC) was
225 ng/hour ∗ mL (data on file, Amgen, Inc.) comparable
to a patient receiving the 60 mg dose of cinacalcet HCl
(AUC 215 ng/hour ∗ mL) (data on file, Amgen, Inc.),
which is used in the clinical setting [15]. Although the ef-
fect of this dose on parathyroid hyperplasia in the clinic
has not yet been confirmed, these data suggest that the
antiproliferative effect described in this report may be
reproducible in humans at clinically achievable concen-
trations of drug.
While hyperplasia correlated well with serum PTH and
ionized calcium as previously reported [17, 18], this was
not the case with serum phosphorus. The lack of correla-
tion between hyperplasia and circulating phosphorus lev-
els was surprising, considering studies indicating a role for
phosphorus in parathyroid hyperplasia [3, 4]. However,
the CaR, rather than serum phosphorus, is probably the
dominant factor involved in parathyroid gland enlarge-
ment and regulation of PTH secretion in vivo [19].
Although low serum vitamin D3, low calcium, and el-
evated phosphorus are thought to contribute to devel-
opment of parathyroid gland hyperplasia [2, 3, 20–23],
increasing evidence suggests the CaR also plays an im-
portant role [11, 16, 17]. Parathyroid hyperplasia is a
characteristic of familial benign hypocalciuric hypercal-
cemia and neonatal severe hyperparathyroidism arising
from inactivating CaR mutations [24]. These clinical ob-
servations were confirmed in the CaR knockout mouse, a
genetic model for neonatal severe hyperparathyroidism
[25]. Furthermore, CaR expression in parathyroid tissue
is down-regulated in uremic rats, in patients with sec-
ondary HPT, and in adenomas from patients with primary
HPT [22, 26–28].
Attenuation of parathyroid hyperplasia by cinacalcet
HCl was independent of serum creatinine levels, thereby
ruling out improved kidney function. Although serum
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Fig. 5. Sham operated rats treated with daily
oral cinacalcet HCl (•) 10 mg/kg (N = 5); ()
5 mg/kg (N = 5); () 1 mg/kg (N = 3); or (◦)
vehicle mL/kg (N = 6) for 4 weeks starting 6
week post-sham surgery. There was an over-
all significant (P < 0.001) treatment effect
of cinacalcet HCl on serum parathyroid hor-
mone (PTH) (A) and blood ionized calcium
levels (B) in serum samples taken 2 hours after
dosing. Post hoc analysis revealed significant
(∗P < 0.05) decreases in serum PTH levels in
the 10 mg/kg dose group at 8 and 10 weeks
and at 10 weeks in the 5 mg/kg group. Blood
ionized calcium was significant post hoc for all
doses at the 8- and 10-week time points. Con-
trol normal animals received no treatment or
surgery (). Values represent mean ± SEM
(N = 3 to 6 animals per dose group).
vitamin D3 levels were not measured in the present stud-
ies, previous studies using NPS R-568 in 5/6 nephrec-
tomized rats demonstrated no elevation in vitamin D3
levels in response to calcimimetic treatment [11], sug-
gesting that elevated vitamin D3 levels are not involved.
Furthermore, a recent study [29] challenges the view that
vitamin D sterols are key modifiers of parathyroid gland
hyperplasia. Mice homozygous for inactivating mutations
of the vitamin D receptor develop characteristics consis-
tent with the inability to respond to vitamin D sterols
including parathyroid gland hyperplasia. A high calcium
diet supplemented with lactose to enhance passive intesti-
nal calcium absorption prevented hyperplasia [29]. Taken
together, these results suggest that calcium, probably act-
ing through the CaR, is a more important determinant
of parathyroid gland hyperplasia than vitamin D sterols.
Cinacalcet HCl may therefore provide another means for
controlling parathyroid hyperplasia.
Parathyroid gland hyperplasia is an important contrib-
utor to excess PTH secretion in patients with secondary
HPT and often accounts for disease progression. It has
been demonstrated clinically that vitamin D3 pulse ther-
apy can be effective in reducing hyperplasia in patients
with mild to moderate secondary HPT, although patients
have been refractory to vitamin D sterol therapy [30, 31].
PTH synthesis and secretion and parathyroid cell prolif-
eration are inhibited by high concentrations of extracel-
lular calcium in vivo [11]. This suggests that calcimimetics
like cinacalcet HCl might be a more effective alternative,
and the attenuation of parathyroid gland hyperplasia by
cinacalcet HCl observed in this study may have important
clinical relevance.
High dietary phosphorus will exacerbate uremia-
induced parathyroid gland hyperplasia and PTH synthe-
sis and secretion. Once secondary HPT develops, dietary
P restriction or phosphate binders can return high PTH
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Fig. 6. Analysis of the correlations between serum levels of blood ion-
ized calcium, phosphorus, or parathyroid hormone (PTH) with parathy-
roid weight in 5/6 nephrectomized animals receiving cinacalcet HCl (10
mg/kg) (closed symbols) or vehicle (open symbols).
levels toward normal, however, parathyroid hyperpla-
sia persists and unwanted side effects can occur [4, 3,
32]. Although the present studies demonstrated no in-
creases in serum phosphorus with cinacalcet HCl, there
are reports demonstrating that calcimimetics can increase
serum phosphorus in normal and uremic rats [11, 12, 17,
18]. Inconsistency between reports may reflect sampling
time relative to cinacalcet HCl administration and/or
the calcimimetic utilized. While hyperphosphatemia in
chronic renal insufficiency has been proposed as the ma-
jor driving force for parathyroid cell hyperplasia [4],
elevations in serum phosphorus do not appear to ham-
per the pronounced calcimimetic-mediated suppressive
action on parathyroid proliferation [11, 17]. Inhibition
of cellular hyperplasia following calcitriol administration
has been associated with an increase of both serum cal-
cium and phosphorus levels, suggesting that increases in
serum calcium can overpower the proliferate actions of
serum phosphorus [2]. Recent clinical studies in end-stage
renal disease (ESRD) patients on dialysis demonstrate
reductions in plasma intact PTH and serum calcium,
phosphorus, and calcium-phosphorus product following
treatment with cinacalcet HCl [13–15].
Parathyroid cell proliferation likely involves a complex
cascade of biochemical signaling pathways which may be
mediated, at least in part, through CaR activation. Al-
though the second-messenger pathways involved in CaR
signaling and their roles in parathyroid proliferation have
not been fully delineated, they have been shown to in-
clude phospholipases, several mitogen-activated protein
kinase (MAPK) cascades, and adenylate cyclase inhibi-
tion through multiple mechanisms [33–35]. Inhibition of
parathyroid hyperplasia by cinacalcet HCl may reflect a
specific CaR signaling pathway associated with growth
mechanisms in these cells.
Several reports have demonstrated that few parathy-
roid cells undergo apoptosis in normal, uremic, or uremic
rats treated with vitamin D3 or with a phosphorus-
restricted diet [3, 36, 37]. Calcimimetics did not induce
parathyroid cell apoptosis in 5/6 nephrectomy or sham
rats in either the present or a previous study by Wada
et al [11]. However, if apoptosis was occurring, it was
unlikely that the present study would reveal this phe-
nomenon because sampling occurred several weeks after
cinacalcet HCl administration and the process of apop-
tosis occurs very early. Thus, additional apoptotic studies
are warranted at earlier time points (24 to 72 hours) post-
cinacalcet HCl administration in uremic rats.
Parathyroid cells are quiescent under normal phys-
iologic conditions [1, 4]; the normal physiologic state
was not perturbed in sham-operated animals receiving
cinacalcet HCl or vehicle, in agreement with previous
studies using NPS R-568 [11, 17, 18]. Our in vivo rat
studies are consistent with previous in vitro data demon-
strating that changes in extracellular calcium had no ef-
fect on proliferation of parathyroid cells derived from
normal chick, rat, or bovine tissues [38–40], but did in
cells derived from uremic animals or patients [41]. Al-
though the mechanism of action behind the difference
in responses has not yet been elucidated, it could re-
sult from alterations in postreceptor signal transduction
associated with hyperparathyroid states. Alternatively,
parathyroid cells could express multiple CaR-like pro-
teins. Evidence indicates that CaR is down-regulated in
hyperplastic tissue; therefore, parathyroid proliferation
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by calcium might occur through a CaR isoform [41]. How-
ever, cinacalcet HCl–treated sham animals do mediate
a decrease in serum PTH, as expected by lowering the
threshold for activation of the CaR by extracellular cal-
cium ions. This difference in detecting a decrease in PTH
secretion versus no change on parathyroid cell prolifera-
tion in sham animals could simply reflect the sensitivity
of the assay systems available to assess serum PTH levels
versus the histomorphometry required to detect changes
in parathyroid gland proliferation in normal animals.
The CaR is present on numerous cell/tissue types;
therefore, it was important to demonstrate that the an-
tiproliferative actions of cinacalcet HCl were specific to
parathyroid tissue and not the result of general cytotox-
icity. Cinacalcet HCl had no effect on intestinal epithe-
lial cells. These results agree with a previous finding that
NPS R-568 had no antiproliferative actions on intestinal
epithelial cells and thyroidal C cells [11]. This is in con-
trast to vitamin D3, which, like cinacalcet HCl, is a very
effective inhibitor of parathyroid hyperplasia, but, unlike
cinacalcet HCl, vitamin D3 also inhibits cell proliferation
in a variety of cell types, including intestinal mucosa [2].
In addition to attenuating parathyroid hyperplasia,
cinacalcet HCl caused rapid dose-dependent decreases
in serum PTH and blood ionized calcium in 5/6 nephrec-
tomized rats. These findings agree with studies with
cinacalcet HCl in normal rats [12, 42]. Reduction in
blood-ionized calcium has also been observed using NPS
R-568 in acutely nephrectomized animals, suggesting that
the mechanism for the observed serum calcium reduc-
tions in response to calcimimetic treatment does not in-
volve the kidney CaR [43]. Calcimimetics in rats cause
a transient increase in serum calcitonin that contributes
to the rate of onset of the observed decrease in serum
calcium levels [12, 43]. As pointed out by Nemeth et al
[12], calcimimetics depress serum PTH levels at doses
that are at least 10 to 30 times lower than those that in-
crease plasma calcitonin levels.
CONCLUSION
Cinacalcet HCl treatment attenuated parathyroid
gland hyperplasia and reduced serum PTH levels in CKD
rats with elevated PTH, most likely through direct actions
on the CaR. Since parathyroid hyperplasia is initiated at
an early stage of CKD and is often refractory to current
medical treatment, the CaR is a potentially useful target
for therapeutic agents like cinacalcet HCl to reduce PTH
secretion, decrease calcium × phosphorus levels and at-
tenuate parathyroid gland hyperplasia in ESRD patients
with secondary HPT.
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